Friday, October 30, 2026
Via News Knowledge File

Microsoft Corporation

organization80% conf.·synced Oct 29, 2026

Technology company partnering with Shopify for Copilot shopping integration

60
sourced metrics
2269
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
3869303244450USD
Oct 22, 2026reference only
Price 52 Week Low
352.83USD
Oct 22, 2026reference only
Stock Price
521.08USD
Oct 22, 2026reference only
Price 52 Week High
543.45USD
Oct 22, 2026reference only
Stock Return Ytd
10.2%
Oct 22, 2026reference only
Shares Outstanding
7425545491.0shares
Jul 23, 2026reference only
Capex
115948000000.0USD
Jun 30, 2026reference only
Operating Income
155237000000.0USD
Jun 30, 2026reference only
Total Liabilities
315989000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
182935000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
106374000000.0USD
Jun 30, 2026reference only
Rd Expense
35562000000.0USD
Jun 30, 2026reference only
Gross Profit
225465000000.0USD
Jun 30, 2026reference only
Revenue
331839000000.0USD
Jun 30, 2026reference only
Total Assets
758376000000.0USD
Jun 30, 2026reference only
Cash
20935000000.0USD
Jun 30, 2026reference only
Net Income
133749000000.0USD
Jun 30, 2026reference only
Stockholders Equity
442387000000.0USD
Jun 30, 2026reference only

Stated objectives

Train 3 million people in AI skills

source
target: 3000000 by 2027-01-01 00:00:00stated

Q2 FY2026 total company revenue target

source
target: 79.5 to 80.6 billion USD stated

Q2 FY2026 Productivity and Business Processes revenue target

source
target: 33.3 to 33.6 billion USD stated

Q2 FY2026 Intelligent Cloud revenue target

source
target: 32.25 to 32.55 billion USD stated

Q2 FY2026 More Personal Computing revenue target

source
target: 13.95 to 14.45 billion USD stated

Increase total AI capacity by more than 80% this year

source
target: 80+ percent increase stated

Roughly double total data center footprint over the next two years

source
target: 2x current footprint by 2027-01-01 00:00:00stated

Scale Fairwater AI superfactories to hundreds of thousands of NVIDIA Vera Rubin Superchips

source
target: hundreds of thousands of Superchips stated

Ensure towns and cities near data center development sites are not adversely affected by electricity costs

source
stated

Enhance cloud and AI infrastructure, cybersecurity, and workforce skills across various industries including healthcare in Poland

source
target: 2.8 billion PLN by 2025-02-01 00:00:00stated

Relationship graph · 2269 connections

Developed by
544
Competes with
447
Covered by
198
Supplies to
195
Invested in
138
Customer of
117
subsidiary of
95
Employs
82

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com